Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: | Recruiting |
---|---|
Conditions: | Prostate Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/31/2019 |
Start Date: | June 30, 2017 |
End Date: | November 18, 2023 |
Contact: | Reference Study ID Number: CO39303 www.roche.com/about_roche/roche_worldwide.htm |
Email: | global-roche-genentech-trials@gene.com |
Phone: | 888-662-6728 (U.S.Only) |
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus
abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant
prostate cancer (mCRPC).
ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus
abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant
prostate cancer (mCRPC).
Inclusion Criteria:
- Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening
- Adequate hematologic and organ function within 28 days before the first study
treatment
- Ability to comply with the study protocol, in the investigator's judgment
- Willingness and ability of participants to use the electronic device to report
selected study outcomes; Caregivers and site staff can assist with patient diary input
but patient must be able to independently comprehend and answer the questionnaires
- Life expectancy of at least 6 months
- Agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures, and agreement to refrain from donating sperm
- For enrollment into the China extension cohort, residence in the People's Republic of
China
Disease-specific Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma without neuroendocrine
differentiation or small-cell features
- Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred)
or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most
recently collected, available tumor tissue accompanied by an associated pathology
report (with tumor content information, Gleason score, and disease staging) for PTEN
IHC and NGS testing and for other protocol-mandated secondary and exploratory
assessments. If only 12-14 slides are available, the patient may still be eligible for
the study, after discussion with and approval by the Medical Monitor. Cytologic or
fine-needle aspiration samples are not acceptable. Tumor tissue from bone metastases
is not acceptable
- A valid PTEN IHC result (testingcentral laboratory tested with results directly sent
to IxRS) (e.g., participants with an "invalid" or "failed" PTEN IHC result are not
permitted to enroll)
- Metastatic disease documented prior to randomization by clear evidence of bone lesions
on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or
magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1
- Asymptomatic or mildly symptomatic form of prostate cancer
- Progressive disease before initiating study treatment
- Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or
bilateral orchiectomy, with serum testosterone <= 50 ng/dL (<= 1.7 nmol/L) within 28
days before randomization
Exclusion Criteria:
- Inability or unwillingness to swallow whole pills
- History of malabsorption syndrome or other condition that would interfere with enteral
absorption
- Clinically significant history of liver disease consistent with Child-Pugh Class B or
C, including cirrhosis, current alcohol abuse, or current known active infection with
hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Need of more than 10 mg/day of prednisone or an equivalent dose of other
anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to
treat a chronic disease (e.g., rheumatic disorder)
- Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1,
Cycle 1
- Immunocompromised status because of current known active infection with HIV or because
of the use of immunosuppressive therapies for other conditions
- Major surgical procedure or significant traumatic injury within 28 days prior to Day
1, Cycle 1, or anticipation of the need for major surgery during study treatment
- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such
as structural heart disease (e.g., severe left ventricular systolic dysfunction, left
ventricular hypertrophy), untreated coronary heart disease (symptomatic or with
ischemia demonstrated by diagnostic testing), myocardial infarction or atrial
thrombotic events within the past 6 months, severe unstable angina, New York Heart
Association Class III and IV heart disease or depressed left ventricular ejection
fraction (LVEF; previously documented LVEF < 50% without documentation of recovery),
clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia,
hypocalcemia), or family history of sudden unexplained death or long QT syndrome
- History of another malignancy within 5 years prior to randomization, except for either
adequately treated non-melanomatous carcinoma of the skin, adequately treated melanoma
in situ, adequately treated non-muscle-invasive urothelial carcinoma of the bladder
(Tis, Ta, and low grade T1 tumors), or other malignancies where the patient has
undergone potentially curative therapy with no evidence of disease and are deemed by
the treating physician to have a recurrence rate of <5% at 5 years
- Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical
examination finding, or clinical laboratory finding giving reasonable suspicion of a
disease or condition that contraindicates the use of an investigational drug or that
may affect the interpretation of the results or renders the participants at high risk
from treatment complications.
Disease-Specific Exclusion Criteria:
- Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the
prostate
- Any therapy including chemotherapy (e.g., docetaxel) or biological therapy (e.g.,
vaccine, immunotherapy) for the treatment of castration-resistant prostate cancer.
Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens,
bicalutamide, nilutamide, or 5-α reductase inhibitor is permitted.
- Use of opioid medications for cancer-related pain, including codeine and
dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1
- Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g.,
ketoconazole, orteronel) or investigational agents that block androgen synthesis.
Previous treatment with itraconazole and fluconazole is permitted.
- Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved
or experimental (e.g., ARN-509, ODM-201, or galeterone)
- Prior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone
acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of
Cycle 1, Day 1
- Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks
of Cycle 1, Day 1
- Prior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1
- Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and
strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal
palliative radiation to treat cancer-related pain is permitted provided that the last
treatment with radiation is at least 14 days prior to Cycle 1, Day 1.
- Prior treatment with approved or experimental therapeutic agents with known inhibition
of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors
- Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day
1
- Known untreated or active central nervous system (CNS) metastases (progressing or
requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT
or MRI scan of the brain will be performed at screening if required by the local
health authority
- Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or
inhibitors or sensitive substrates of CYP3A or CYP2D6 with a narrow therapeutic window
Abiraterone-Specific Exclusion Criteria:
- Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood
pressure ≥ 95 mmHg)
- History of pituitary or adrenal dysfunction
- Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical
therapy
Ipatasertib-Specific Exclusion Criteria:
- Type 1 or Type 2 diabetes mellitus requiring insulin at study entry
- History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis),
active bowel inflammation (e.g., diverticulitis)
We found this trial at
52
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Click here to add this to my saved trials
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
263 Farmington Ave
Farmington, Connecticut 06030
Farmington, Connecticut 06030
(860) 679-2000
University of Connecticut Health Center UConn Health is a vibrant, integrated academic medical center that...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
Click here to add this to my saved trials
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
Click here to add this to my saved trials
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Madigan Army Medical Center Located on Joint Base Lewis-McChord, Madigan Army Medical Center comprises a...
Click here to add this to my saved trials
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
Washington, District of Columbia 20007
(202) 687-7695
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
Click here to add this to my saved trials